Degludec: The New Ultra-long Insulin Analogue

dc.creatorTambascia
dc.creatorMarcos Antonio; Eliaschewitz
dc.creatorFreddy Goldberg
dc.date2015-Jun
dc.date2016-06-07T13:21:36Z
dc.date2016-06-07T13:21:36Z
dc.date.accessioned2018-03-29T01:41:23Z
dc.date.available2018-03-29T01:41:23Z
dc.identifier
dc.identifierDegludec: The New Ultra-long Insulin Analogue. Biomed Central Ltd, v. 7, p. Jun-2015.
dc.identifier1758-5996
dc.identifierWOS:000357072300001
dc.identifier10.1186/s13098-015-0037-0
dc.identifierhttp://dmsjournal.biomedcentral.com/articles/10.1186/s13098-015-0037-0
dc.identifierhttp://repositorio.unicamp.br/jspui/handle/REPOSIP/243095
dc.identifier.urihttp://repositorioslatinoamericanos.uchile.cl/handle/2250/1306793
dc.descriptionThe development of extended-action insulin analogues was motivated by the unfavorable pharmacokinetic (PK) profile of the conventional long-acting insulin formulations, generally associated with marked inter and intra patient variability and site-and dose-dependent effect variation. The new ultra-long insulin analogue degludec (IDeg) has the same amino acid sequence as human insulin except for the removal of threonine in the position 30 of the B chain (Des-B30, "De") and the attachment, via a glutamic acid linker ("glu"), of a 16-carbon fatty diacid (hexadecanoic diacid, "dec") to lysine in the position 29 of the B chain. These modifications allow that, after changing from the pharmaceutical formulation to the subcutaneous environment, IDeg precipitates in the subcutaneous tissue, forming a depot that undergoes a highly predictable gradual dissociation. Thus, once-daily dosing of IDeg results in a low peak: trough ratio, with consequent low intra-individual variability and plasmatic concentrations less critically dependent upon the time of injections. The clinical development program of IDeg (BEGIN) was comprised of 9 therapeutic confirmatory trials of longer duration (26-52 weeks) and showed that the efficacy of IDeg is comparable to insulin glargine in type 1 (T1D) and type 2 (T2D) diabetes patients across different age, body mass index and ethnic groups. This new ultra-long insulin analogue presents as advantages flexibility in dose timing and lower risk of hypoglycemia.
dc.description7
dc.description
dc.description
dc.description
dc.description
dc.descriptionNovo Nordisk Inc.
dc.description
dc.description
dc.description
dc.languageen
dc.publisherBIOMED CENTRAL LTD
dc.publisher
dc.publisherLONDON
dc.relationDIABETOLOGY & METABOLIC SYNDROME
dc.rightsaberto
dc.sourceWOS
dc.subjectTo-target Trial
dc.subjectNocturnal Hypoglycemia
dc.subjectGlycemic Control
dc.subjectBasal Insulin
dc.subjectNph Insulin
dc.subjectGlargine
dc.subjectPharmacokinetics
dc.subjectMetaanalysis
dc.subjectAssociation
dc.subjectVariability
dc.titleDegludec: The New Ultra-long Insulin Analogue
dc.typeArtículos de revistas
dc.typeResumo


Este ítem pertenece a la siguiente institución